Articles

Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners

Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners

Zenitar is a structure-based biology and AI-driven innovative drug R&D company, focused on unmet clinical needs in major therapeutic areas including oncology, autoimmune diseases, inflammation, and neurological disorders. The company is dedicated to discovering, developing, and commercializing first-in-class and best-in-class innovative medicines.

Q&A | Duane Kuang and Qianli Technology's Qi Yin: Closed-Loop Business Models Sustain Tech Progress, AI Era Offers Huge Hardware Opportunities

Q&A | Duane Kuang and Qianli Technology's Qi Yin: Closed-Loop Business Models Sustain Tech Progress, AI Era Offers Huge Hardware Opportunities

Because of the changes brought by AI Agent assistants and operating systems, many different hardware form factors will emerge in the future before gradually converging. This is a space where both tech giants and startups will have significant opportunities.

Evolutionary Tide Raises Hundreds of Millions of Yuan in Pre-A Round, Qiming Venture Partners Co-Leads

Evolutionary Tide Raises Hundreds of Millions of Yuan in Pre-A Round, Qiming Venture Partners Co-Leads

Emergent Tide is built on original research from the Tsinghua University School of Medicine team in the field of humoral immunity, developing novel therapeutics for inflammatory and autoimmune diseases against a first-in-class global target, addressing core challenges in the field and significant unmet clinical needs.